Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222280 · ClinicalTrials.gov registry record · NA
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
A NA study of Alzheimer Disease and Alzheimer Dementia, sponsored by Covenant Health, US.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT07222280: Recruiting NA study of Alzheimer Disease and Alzheimer Dementia, sponsored by Covenant Health, US.
NCT07222280 is a NA study of Alzheimer Disease and Alzheimer Dementia that is actively recruiting participants, run by Covenant Health, US. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222280, a NA study of Alzheimer Disease and Alzheimer Dementia, is actively recruiting participants, sponsored by Covenant Health, US.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Primary Outcome
A Six month follow up with the Neurology clinic to discuss the results of Quest AD Detect (p-tau217), those patients who are found to have a positive outcome will receive additional follow-up in the Neurology clinic (which could include the use of additional lab tests or further diagnostic testing).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Quest AD-Detect blood test
Study Locations (6)
Tennessee
- Cumberland Medical Center - Crossville
- Roane Medical Center - Harriman
- Fort Sanders Regional Medical Center - Knoxville
- Fort Loudon Medical Center - Lenoir City
- Methodist Medical Center - Oak Ridge
- LeConte Medical Center - Sevierville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What NCT07222280 shows while recruiting
NCT07222280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Quest AD-Detect blood test is the first listed.
NCT07222280 lists 6 locations in 1 state (Tennessee).
Frequently Asked Questions
What is clinical trial NCT07222280 about?
NCT07222280 is a clinical study titled "Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy". The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the abilit...
What is the current status of trial NCT07222280?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-10. Estimated completion is 2026-03-31.
What conditions does trial NCT07222280 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Dementia, Encephalopathy, Delirium Confusional State, Cognitive Abnormality.
What interventions are being tested in trial NCT07222280?
The interventions under investigation include: Quest AD-Detect blood test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07222280?
This trial is sponsored by Covenant Health, US, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222280 being conducted?
This trial has 6 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222280's enrollment target sits among peer trials
30 239th of 306 higher than 56 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI